Author | Andre H. Goy, MD, MS | OncLive

Author | Andre H. Goy, MD, MS

Articles

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

May 10, 2020

Video

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Dr. Goy on the Utility of Novel Agents in MCL

February 04, 2020

Video

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).

Dr. Goy on Preliminary Data With Ibrutinib/Venetoclax in Relapsed/Refractory MCL

January 14, 2020

Video

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses preliminary data with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

x